Breathlessness is a dangerous symptom. Preliminary data from national and regional Danish databases show, that patients with shortness of breath in the ambulance have a very high mortality. Breathlessness can be caused by many different conditions - but heart diseases and lung diseases are dominant. The mortality is especially high in patients with breathlessness caused by heart disease. Distinguishing these different causes of breathlessness is a classical, often difficult, discipline in medicine. Visitation and guidance of treatment in patients with breathlessness in the prehospital setting relies on medical history and physical examination and as a consequence prehospital treatment for breathlessness is often non-specific. The use of heart-failure specific biomarkers may improve prehospital visitation and treatment of patients with breathlessness. We hypothesize, that 1. Supplementing the routine examination by prehospital anesthesiologist with measurement of a biomarker for heart failure increases the proportion of patients with severe shortness of breath caused by heart disease triaged directly to department of cardiology 2. This strategy does not increase the proportion of patients with severe shortness of breath caused by non-heart disease triaged directly to department of cardiology
Measurement of the biomarker for heart failure N-terminal pro-Brain Natriuretic Peptide (NT-proBNP): In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted. This will be analyzed point-of-care in the ambulance. Interpretation of NT-proBNP: Cut-off values based on bootstrap-validated optimal cut-points for heart failure on will be used. Confirmatory ('rule in') cut point \< 50 years: 450 pg/mL 50-75 years: 900 pg/mL \> 75 years: 1800 pg/mL Exclusionary ('rule out') cut point All patients: 300 pg/mL The emergency physicians will be thoroughly informed about these cut-points, but told not to triage to department of cardiology or other department strictly according to NT-proBNP, but according to clinical assessment AND NT-proBNP.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
712
In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
Critical Care Team Aarhus, Prehospital Emergency Medical Services
Aarhus, Central Jutland, Denmark
Critical Care Team Grenaa, Prehospital Emergency Medical Services
Grenå, Central Jutland, Denmark
Critical Care Team Herning, Prehospital Emergency Medical Services
Herning, Central Jutland, Denmark
Critical Care Team Holstebro
Holstebro, Central Jutland, Denmark
Critical Care Team Horsens, Prehospital Emergency Medical Services
Horsens, Central Jutland, Denmark
Critical Care Team, Lemvig, Prehospital Emergency Medical Services
Lemvig, Central Jutland, Denmark
Critical Care Team Randers, Prehospital Emergency Medical Services
Randers, Central Jutland, Denmark
Critical Care Team Silkeborg, Prehospital Emergency Medical Services
Silkeborg, Central Jutland, Denmark
Critical Care Team, Viborg, Prehospital Emergency Medical Services
Viborg, Central Jutland, Denmark
Proportion of patients with dyspnea caused by heart disease initially triaged to department of cardiology
An endpoint committee determines final diagnoses as "dyspnea caused by heart disease", "dyspnea caused by lung disease" and "dyspnea caused by other diseases" based on clinical and paraclinical data excluding prehospital NT-pro-BNP value
Time frame: Within 1 day from randomization
Proportion of patients with dyspnea of other etiologies initially triaged to department of cardiology
An endpoint committee determines final diagnoses as "dyspnea of cardiac origin" and "dyspnea of non-cardiac origin" based on clinical and paraclinical data excluding prehospital NT-pro-BNP value
Time frame: Within 1 day from randomization
Proportion of patients with dyspnea caused by heart disease that receives pulmonary medication
beta2-agonist inhalations, combined ipratropium/b2-agonist inhalations, intravenous b2-agonists, intravenous corticosteroids
Time frame: Within 1 day
Length of hospital stay
Time from hospital admission related to the inclusion event to discharge from hospital
Time frame: Up to three months from randomization
Intensive care unit admission rate
Within the time from hospital admission related to the inclusion event to discharge from hospital related to inclusion event
Time frame: Up to three months from randomization
All-cause re-admission
Time frame: Within 3 months of randomization
Proportion of patients not admitted to hospital
Proportion of patients not admitted to hospital in relation to the inclusion event
Time frame: Within 24 hours
All-cause mortality
Time frame: Within 30 days of randomization
Proportion of patients with dyspnea caused by lung disease, that receives traditional heart failure medication
Loop diuretics, nitrates, opiates
Time frame: Within 1 day
Proportion of patients with correct diagnosis of congestive heart failure in the prehospital setting
An endpoint committee determines final diagnoses based on clinical and paraclinical data excluding prehospital NT-pro-BNP value
Time frame: Within 1 day of randomization
Proportion of patients where congestive heart failure is correctly disproved in the prehospital setting
An endpoint committee determines final diagnoses based on clinical and paraclinical data excluding prehospital NT-pro-BNP value
Time frame: Within 1 day of randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.